Application of Cervista® human papilloma virus high-risk test in cervical cancer screening of Xinjiang Uyghur women.
This study aims to evaluate the diagnostic value of the Cervista® human papilloma virus (HPV) high-risk (HR) test in cer- vical cancer and precancerous lesion screening in Xinjiang Uyghur women. Three hundred and seventy three Uyghur women from Bachu County underwent the Cervista® HPV HR test, ThinPrep cytologic test, and cervical biopsy under a colposcope. Then the relationship between the infection rate of high-risk human papilloma virus (HR-HPV), the cytological results, and the histological results was analyzed. With increasing cytological and pathological classification, the HR-HPV infection rate also increased and reached 100% in patients with cervical cancer. The highest proportion of the pathologically positive group consisted of patients with group A9 HPV infection as compared to patients infected with group A5/A6 or A7 HPV. HR-HPV is closely correlated with cervical cancer and precancerous lesions. Group A9 HPV has a high predictive value in cervical disease screening in Uyghur women. When cytological examination shows atypical squamous cells of undetermined significance (ASCUS), the Cervista® HPV HR test can provide a sensitive differentiation method.